RNA profiling has emerged as a powerful tool to investigate the biomarker potential of 18 human biofluids. However, despite enormous interest in extracellular nucleic acids, RNA 19 sequencing methods to quantify the total RNA content outside cells are rare. Here, we evaluate the 20 performance of the SMARTer Stranded Total RNA-Seq method in human platelet-rich plasma, 21 platelet-free plasma, urine, conditioned medium, and extracellular vesicles (EVs) from these 22 biofluids. We found the method to be accurate, precise, compatible with low-input volumes and 23 able to quantify a few thousand genes. We picked up distinct classes of RNA molecules, including 24 mRNA, lncRNA, circRNA, miscRNA and pseudogenes. Notably, the read distribution and gene 25 content drastically differ among biofluids. In conclusion, we are the first to show that the SMARTer 26 method can be used for unbiased unraveling of the complete transcriptome of a wide range of 27 biofluids and their extracellular vesicles. 28 30 31 2 of 15 1. Introduction
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transcripts and the total number of spike-in reads is a relative measure for the RNA concentration of 135 the various samples. When adding the same amount of ERCC RNA to all samples, a higher ratio is 136 indicative of more endogenous RNA. We found the highest RNA extraction concentration in 137 conditioned medium, and the lowest in plasma EVs (SupFig6). Of note, not all starting volumes 138 before EV purifications or other handling were equal. For instance, in our urine experiment we 139 compare RNA extracted from 200 uL whole urine with RNA isolated from EVs that were present in 140 45 mL whole urine as starting material. Therefore, we corrected the endogenous:ERCC ratios for the 141 original input volumes. This provides us information about the relative amount of RNA present per 142 milliliter biofluid ( Fig 3A) . While ePRP, conditioned medium and urine have very similar RNA 143 concentrations, ePFP and cPFP contain approximately 17 times less RNA. In addition, EVs from 144 condition medium hold 2763 times less RNA compared to their fluid of origin, plasma EVs 616 times 145 less and urine EVs 7.6 times less. Given that only one biological sample was included in this 146 experiment, further studies warranted to validate these differences in RNA concentration.
148
In a separate experiment, we added two different spike-in mixes in varying amounts to five identical 149 ePFP samples from a fourth healthy donor. Sequin spikes (n=78) and ERCC spikes (n=92) were diluted 150 in opposite order by a factor 1.41 in the five derivative samples. In this way, a biologically relevant 4-151 fold dynamic range for both Sequin and ERCC spikes was covered ( Fig 1C) . The aim of this 152 experiment was to assess the method's trueness by comparing expected and observed fold changes 153 of the 170 sequenced spike-in RNAs. Of note, both Sequin and ERCC spike mixes consist of multiple 154 RNA molecules present in varying concentrations. Based on pre-experiments, we made sure that we 155 added the spikes in such amounts that the number of reads going to the spikes with the highest 156 concentration (for both the Sequin and ERCC panel) was lower than the number of reads going to the 157 10 th highest abundant endogenous gene. Only by aiming for coverage in the biofluid abundance 158 range, one is able to assess the accuracy of biologically relevant differences. The results indicate how 159 reliably fold changes can be detected using our total RNA seq method. Overall, there is a strong 160 correlation between the expected and observed fold changes, with ERCC spikes (slope=0.975, 161 adjusted R 2 = 0.67) behaving slightly better than Sequin spikes (slope=0.895, adjusted R 2 = 0.78) since 162 the slope is expected to be '1' (Fig 3B) . Notably, larger variations arise when assessing smaller fold 163 changes. Indeed, the lower the fold change, the bigger the spread in datapoints in the violin plot. We 164 investigated this observation in more detail and found that deviation from the expected value is 165 larger for spikes with fewer counts ( Fig 3C) . In order to reliably measure small fold changes, it 166 appears that a minimal number of 10 counts is advisable. Importantly, for about 90% of the spikes 167 the deviation between the observed and expected log2 fold change is smaller than 0.5. This is shown 168 in the cumulative distribution plot, where a minimum of 87.3% (for a log2 fold change difference of 169 1) and a maximum of 91.4 % (for a difference of 2) of the spikes show a deviation from the expected 170 value of maximum 0.5 ( Fig 3D) . This indicates that the worst measurement for about 90% of the spikes 171 is wrong with only a factor 1.41. What is more, almost all spikes can be measured within an error of 172 a factor 2. In conclusion, although very small fold changes and fold changes of lower abundant 173 transcripts are somewhat more difficult to detect, the method is reliable and approximates true fold 174 changes very well.
176
2.3. The total RNA seq method is reproducible 177 178
As indicated above, technical replicates of the e PRP and ePFP samples were prepared at the level of 179 RNA isolation. Scatter plots of the read counts clearly show that gene counts are reproducible 180 between independent RNA extractions of the same plasma sample (Fig 4) . In addition, we generated 181 cumulative distribution plots that display the fold change of every gene when comparing RNA 182 isolation replicates ( Fig 5A) . The area left of the curve (ALC) indicates the precision of the method,
183
with lower values demonstrating better replication. Indeed, the more the curves are shifted to the 184 left, the smaller the differences between two replicates and thus the smaller the ALC value. In 185 biological terms, this means that half of the genes can be detected with a fold change smaller than the 186 5 of 15 ALC value. To illustrate, in ePRP of donor 2 half of the genes show a fold change less than 1.32 187 between both replicates (log2 fold change of 0.403, indicated in Fig 5C) . Cumulative distribution plots 188 for the experiment with conditioned medium, citrate plasma, urine and their respective EVs ( Fig 5B) .
189
show slightly lower ALC values, indicating that reproducibility is better when replication is 190 introduced at the level of library preparation ( Fig 5C) reproducibly detected genes (mRNA, lncRNA, miscRNA pseudogenes and others), ePFP samples 200 contain more genes compared to ePRP ( Fig 6A) . This is probably due to lower amounts of (very 201 abundant) mitochondrial RNA in ePFP, hence freeing up sequencing power to detect more genes. In 202 addition, the 20 most abundant genes consume approximately 75% of the reads in ePRP,
203
automatically leading to less diversity in the remaining gene fraction ( Fig 6B) . The highest abundant 204 genes in PRP are MTRNR2 (or paralogues), MTND1 and MTND2, which are all transcribed from 205 mitochondrial DNA, as are many other genes in the top-20 (SupFig8). Urine and urinary EVs contain 206 more than 10,000 genes in our experimental setup, the highest number of all evaluated biofluids ( Fig   207   6C ). The lowest number of genes was observed in healthy donor citrate plasma derived EVs, in which 208 only 904 genes could be detected using our total RNA seq method. Interesting to note is that plasma 209 EVs had the worst mapping qualities of all samples (see Fig 2A above ). An important remark is that 210 one should be cautious when interpreting the results above. Indeed, simply comparing gene numbers 211 among different biofluids is difficult because of varying input volumes used for RNA purification.
212
As already exemplified above, in the urine experiment we compare RNA extracted from 200 uL 213 whole urine with RNA isolated from EVs that were present in 45 mL whole urine as starting material.
214
To get further insights in the technical performance of the total RNA seq method, we also assessed 215 the distribution of the counts (SupFig9) and the gene body coverage (SupFig10). In fragmented RNA, 216 the coverage at the 5' and 3' end of the gene body is typically lower compared to the middle part.
218
We further investigated five different gene biotypes in all samples, according to their annotation in 219 Ensembl (protein coding genes, lncRNA genes, miscellaneous RNA genes, pseudogenes and other 220 genes). The percentage of counts assigned to these five gene types differs among the biofluids. ePRP 221 for instance contains high number of pseudogene reads, resulting from mitochondrial genes as 222 illustrated above, whereas ePFP mainly consists of reads mapping to protein coding genes ( Fig 7A) .
223
The differences in the other samples are less explicit. Looking into the top-20 genes with the highest 224 counts reveals the genes consuming most of the reads in each sample (SupFig8). We also calculated 225 the absolute numbers per gene biotype, but again we should keep in mind the difficulty in side-by-226 side comparisons because of differing input volumes ( Fig 7B-C) . What we can conclude is that the 227 method is able to pick up many different classes of RNA molecules.
229
Next to Ensembl, we also assessed the reads mapping to LNCipedia 11 , the most comprehensive 230 database of human long non-coding RNAs ( Fig 8A) . In analogy with the results above, the largest 231 number of lncRNAs was found in urine and urinary EVs. Indeed, approximately 3000 lncRNA genes 232 can be distinguished in EVs isolated from urine. cPFP contains around 1500 lncRNAs, while we could 233 detect almost no lncRNAs in EVs isolated from this plasma. As expected, ePFP contains more 234 lncRNAs than ePRP. In addition, also the presence of circular RNAs was assessed. Their overall 235 number is low, but especially cPFP and urinary EVs show substantially more circular RNAs ( Fig 8B) .
236
CircRNAs are presumed to be more stable and less degraded compared to linear forms. Therefore, 237 they are ideal candidates for cancer biomarker discovery studies. 
268
Proton method 13 and 4) TGIRT-sequencing using thermostable group II intron reverse transcriptases 5 .
269
The SMARTer method assessed in our study adds a fifth promising method to the sequencing 270 armory. In addition, the SMARTer method avoids limitations linked to other methods such as short 271 fragment length, low amount of quantified genes or ribosomal RNA contamination. 
286
It has been shown that pre-analytical variables may have an effect on the resulting RNA profiles 15 . In 287 our study, we also observed differences between ePFP and cPFP, which are identical biofluids 288 collected in different blood tubes and prepared with a slightly different centrifugation protocol. In 289 7 of 15 general, differences in pre-analytical variables such as blood collection tubes, processing time, 290 centrifugation speeds, RNA isolation kit, and freeze-thaw cycles could well be responsible for great 291 variation in RNA sequencing results. Systematic evaluation of the impact of pre-analytical variables 292 would definitely be of huge added value to progress the fields of extracellular RNA research and 293 liquid biopsies.
295
In our study we included synthetic spike-in RNA mixes to control for variation during RNA isolation 296 and/or library preparation. Of note, we did not include spikes during RNA isolation of EVs and their 297 biofluids or origin because we did not include replicates at the RNA level. Ideally however, both 298 Sequin spikes 16 during RNA extraction and ERCC spikes before library preparation are added in all
299
RNA sequencing experiments to control for different types of technical variation. As data 300 interpretation is often complex in experiments involving different biofluids and input volumes, 
332
For the spike-in RNA titration experiment, the protocol was identical except for the fact that 4 EDTA 333 tubes of 10 ml were drawn and that the second centrifugation step was different (1500 g, 15 minutes, 334 room temperature, without brake). 
360
(2 ml per column) and fractions of 1 ml eluate were collected. SEC fractions 4, 5 and 6 were pooled 361 and concentrated to 1 ml using 10 kDa centrifugal filter (Amicon Ultra-2ml, Merck Millipore,
362
Billerica, Massachusetts, USA). The resulting 1 ml sample was loaded on top of a DG, as previously 363 described 18 . This discontinuous iodixanol gradient was prepared by layering 4 ml of 40 %, 4 ml of 20 364 %, 4 ml of 10 % and 3.5 ml of 5 % iodixanol in a 17 ml Thinwall Polypropylene Tube (Beckman 
457
to determine the concentration and size distribution of measured particles with corresponding 458 standard error. For optimal measurements, samples were diluted with PBS until particle 459 concentration was within the optimal concentration range for particle analysis (3x10 8 -1x10 9 ). RNA isolation was performed using the miRNeasy Serum/Plasma Kit (Qiagen). In experiment 1, 473 ePRP and ePFP RNA was isolated from 200 µl of platelet-rich and platelet-free plasma from two 474 healthy donors. Two RNA replicates were included. 2 µl of Sequin RNA spikes 16 were added to the 475 lysate at a dilution of 1/3000 for PFP and 1/250 for PRP, to control for variation in RNA isolation.
476
After isolation, 2µl of ERCC RNA spikes (ThermoFisher) were added to the eluate at a dilution of 477 1/25 000 for PFP and 1/5000 for PRP. This allows to estimate the relative concentration of the eluate.
478
For the ePFP RNA of the healthy donor, used for the spike-in RNA titration experiment (see 4.4), we 479 used 6 aliquots of 200 µl plasma and pooled the RNA after isolation. We did not add Sequin spikes 480 during RNA isolation. ERCC spikes were added following a titration series, as described in the next 481 paragraph. Finally, RNA from EVs and their respective biofluids was isolated with the same kit, using 482 200 µl sample input (see also 4.1). No duplicates were included at the level of RNA isolation, no 483 Sequin spikes were added, and the standard spin columns were replaced by Ultra-Clean Production 484 (UCP) columns (Qiagen). ERCC spikes were added to the RNA isolation eluate at a dilution of 1/30 485 000 for plasma and urine and 1/50 for conditioned medium. Pooled ePFP RNA (prepared without Sequin spike-in RNA addition) was distributed in five separate 490 tubes, each containing 12 µl RNA. Then, we added 1 µl DNase, 1.6 µl reaction buffer, 2 µl Sequin 491 spikes and 2 µl ERCC spikes to each tube. Both spike-in RNA types were added in a 5-point 1.414-492 fold dilution series, in opposing order. For Sequin: 1/15,000, 1/21,277, 1/30,000, 1/42,433 and 1/60,000.
493
For ERCC: 1/100,000, 1/70,721, 1/50,000, 1/35,461 and 1/25,000.
495
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Total RNA library preparation and sequencing 496
On the total amount of 12 µl eluate, gDNA heat-and-run removal was performed by adding 1 497 µl of HL-dsDNase (ArcticZymes 70800-202, 2 U/µl) and 1 µl reaction buffer (ArcticZymes 66001). Of 498 the resulting volume, 4 µl was used as input for the total RNA library preparation protocol.
499
Sequencing libraries were generated using SMARTer Stranded Total RNA-Seq Kit v2 -Pico Input 500 Mammalian (Takara, 634413) . Compared to the manufacturer's protocol, the fragmentation step was 501 set to 4 min at 94 °C, hereafter the option to start from highly degraded RNA was followed. Library The reads with a low quality score (Q30) were discarded, hereafter read duplicates were removed 512 with Clumpify (BBMap v.37.93, standard settings). The libraries were trimmed using cutadapt
513
(v.1.16) 22 to remove 3 nucleotides of the 5' end of read 2. To enable a fair comparison, we started data-514 analysis from an equal number of reads by subsampling to 1 million trimmed and deduplicated 515 reads. To assess the quality of the data, the reads were mapped using STAR (v.2.5.3) 23 on the hg38 516 genome including the full ribosomal DNA (45S, 5.8S and 5S) and mitochondrial DNA sequences. The 517 parameters of STAR were according to the ENCODE project. Using SAMtools (v1.6) 24 ,reads mapping 518 to the different nuclear chromosomes, mitochondrial DNA and rRNA were extracted and annotated 519 as exonic, intronic or intergenic. The SMARTer total RNA sequencing data is stranded and processed 520 accordingly, so strandedness was considered for each analysis step. Gene body coverage was 521 calculated using the full Ensembl (v91) 25 transcriptome. The coverage per percentile was calculated. 
